No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EXAS240517P42500
- 0.06
- -0.20-76.92%
15min DelayClose May 8 15:59 ET
0.10High0.05Low
0.05Open0.26Pre Close43 Volume26 Open Interest42.50Strike Price251.00Turnover107.02%IV-28.67%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.06Time Value100Contract SizeAmericanOptions Type-0.0192Delta0.0046Gamma793.07Leverage Ratio-0.0234Theta-0.0003Rho-15.20Eff Leverage0.0044Vega
Intraday
- 5D
- 1D
News
Exact Sciences Stock Plunges On Q1 Earnings: What You Need To Know
Exact Sciences Corp (NASDAQ:EXAS) shares are trading lower in Wednesday's after-hours session on the heels of the company's first-quarter results. Here's a rundown of the report.What Happened: Exact S
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
Exact Sciences Down 17% on Quarterly Bottom Line Miss, Maintaining 2024 Guidance
Exact Sciences | 10-Q: Quarterly report
Exact Sciences Q1 Net Loss Widens, Revenue Increases; 2024 Revenue Outlook Maintained -- Shares Fall After Hours
Exact Sciences (EXAS) shares were plummeting 12% in after-hours activity Wednesday after reporting wider Q1 net loss. The company's net loss was $0.60 per diluted share, wider than a loss of $0.42 a y
Express News | Exact Sciences Corp Shares Extend After the Bell Losses, Last Down 13.8% at $51.25
Comments
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
Exact Sciences' growth rate is somewhat slow, showing a 20% rise in revenue while lacking profitability at an EBIT level. Considerable liabilities and negative EBIT results make its financial status seem precarious and risky.
Read more